Foghorn Therapeutics (FHTX) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Rani Therapeutics (RANI) has outperformed Foghorn Therapeutics (FHTX) over the past year, gaining 62.4% versus a loss of 52.7%. Over five years, FHTX leads with a -83.1% price change compared with -95.9% for RANI. Foghorn Therapeutics is the larger company by market cap ($124.1 million vs $114.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | RANI |
|---|---|---|
| Share price | $2.09 | $0.8121 |
| Market cap | $124.12M | $114.12M |
| 1-day change | +6.09% | -2.01% |
| YTD return | -61.30% | -39.84% |
| 1-year return | -52.71% | +62.42% |
| 5-year return | -83.12% | -95.88% |
| EPS (TTM) | $-0.98 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $3.87 |
| 52-week low | $1.79 | $0.445 |
| Distance from 52-week high | -72.54% | -79.02% |
| Average volume | 617.56K | 752.29K |
| Shares outstanding | 59.39M | 115.42M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RANI has outperformed FHTX by 115.1 percentage points over the past year.
FHTX vs RANI FAQ
Which is bigger, Foghorn Therapeutics or Rani Therapeutics?
Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $124.12M compared with $114.12M for Rani Therapeutics (RANI).
Which stock has performed better over the past year, FHTX or RANI?
RANI returned +62.42% over the past 12 months, compared with -52.71% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.